Orthocell (OCC) investor relations material

Executive summary

• Achieved strong revenue growth in Q3 FY26, with $3.2M for the quarter and $9.4M year-to-date, a 45% increase year-over-year, already surpassing FY25 full-year revenue.

• U.S. Remplir sales reached $300k in Q3, with March sales at $170k, marking the first material quarter of U.S. sales and indicating a potential inflection point.

• Robust cash reserves of $48M as of March 31, 2026, providing a 4.6-year cash runway and supporting commercial expansion.

• Expanded U.S. distributor network to 16+ states, covering 40% of the population, and secured 32 Value Analysis Committee approvals, granting access to over 115 hospitals.

• International expansion continues with new distributors in the UK, Canada, and Hong Kong, and growing adoption in Australia, New Zealand, and Asia.

Financial highlights

• Q3 FY26 revenue of $3.2M, up 45% compared to the prior corresponding period.

• U.S. revenue for the quarter was $0.3M, up 37% sequentially.

• Year-to-date revenue of $9.4M exceeds FY25 full-year revenue of $9.2M.

• Cash and term deposits total $48M, with $7.8M in cash and $40.2M in term deposits.

• Net cash flows from operating activities were breakeven for the quarter, a $5.9M improvement from the previous quarter.

Outlook and guidance

• Path to breakeven is clear, requiring less than 1% U.S. market share, or 5,000–6,000 procedures annually, achievable with 300–400 active surgeons.

• No additional funding required to reach cash flow breakeven, supported by current cash reserves.

• Anticipates material uplift in U.S. revenue in upcoming quarters as commercial distribution expands.

• UK/EU regulatory approval for Remplir expected in the second half of calendar year 2026.

• Remplir's new application in nerve-sparing prostate cancer surgery could expand the U.S. addressable market from $1.6 billion to $2 billion.